Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10006324HBVENSG00000160752.15protein_codingFDPSNoNo2224A0A087X090
P14324
TVIS10003145HBVENSG00000160752.15protein_codingFDPSNoNo2224A0A087X090
P14324
TVIS10022102HBVENSG00000160752.15protein_codingFDPSNoNo2224A0A087X090
P14324
TVIS10025984HBVENSG00000160752.15protein_codingFDPSNoNo2224A0A087X090
P14324
TVIS10051965HBVENSG00000160752.15protein_codingFDPSNoNo2224A0A087X090
P14324
TVIS10052093HBVENSG00000160752.15protein_codingFDPSNoNo2224A0A087X090
P14324
TVIS30025272HIVENSG00000160752.15protein_codingFDPSNoNo2224A0A087X090
P14324
TVIS30025273HIVENSG00000160752.15protein_codingFDPSNoNo2224A0A087X090
P14324
TCGA Plot Options
Drug Information
GeneFDPS
DrugBank IDDB00282
Drug NamePamidronic acid
Target IDBE0000776
UniProt IDP14324
Regulation Typeinhibitor
PubMed IDs11752352; 10620343; 11160603; 15713990; 12177810; 15487700
CitationsChen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41.@@Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.@@Notarnicola M, Messa C, Cavallini A, Bifulco M, Tecce MF, Eletto D, Di Leo A, Montemurro S, Laezza C, Caruso MG: Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology. 2004;67(5-6):351-8.@@Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC: The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer. 2002 Jul 29;87(3):366-71.@@Zhang PL, Lun M, Siegelmann-Danieli N, Blasick TM, Brown RE: Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. Ann Clin Lab Sci. 2004 Summer;34(3):263-70.
GroupsApproved
Direct ClassificationBisphosphonates
SMILESNCCC(O)(P(O)(O)=O)P(O)(O)=O
PathwaysPamidronate Action Pathway
PharmGKBPA450767
ChEMBLCHEMBL834